Skip to main content
Premium Trial:

Request an Annual Quote

Interpace, Viatar Collaborate on Pancreatic Cancer Studies

NEW YORK (GenomeWeb) – Interpace Diagnostics reported today a research collaboration with Viatar CTC Solutions aimed at assessing indeterminate pancreatic cancer biopsies in patients with pancreatic cysts.

The two firms will use Interpace's PancraGen assay and Viatar's circulating tumor cell technology in studies aimed at identifying patients who are most likely to develop pancreatic cancer in the near future, and at detecting the cancer in the earliest stage of development. The preclinical studies are expected to be conducted during the next six months, Interpace said. It added the studies may lead to the implementation of early diagnostic testing and assessment for patients with pancreatic diseases, as well as patients who are predisposed to developing aggressive and difficult forms of the cancer that are most in need of early detection.

Financial and other terms of the deal were not disclosed.

Interpace's PancraGen assay uses a small sample of pancreatic cyst fluid to assess pancreatic cancer risk. Viatar calls itself a "cancer dialysis" firm. Its lead product, the Viatar Oncopheresis System, removes CTC cells for liters of whole blood based on a filtration method using size and stiffness. 

The Scan

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.

New Oral Nanomedicine Strategy Targets Gut-Brain Axis to Treat IBD

A new paper in Science Advances describes a platform to design polyphenol-armored oral medicines that are effective at treating inflammatory bowel disease.

Phylogenetic Data Enables New Floristic Map

Researchers in Nature Communications use angiosperm phylogenetic data to refine the floristic regions of the world.

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.